Shares of Galmed Pharmaceuticals Ltd. (GLMD) are up over 53% at $2.39 today, on news of the company signing a binding term sheet with Czech company Entomus s.r.o.
The term sheet outlines a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administered GLP-1 drugs.
The marketed GLP-1 drugs include Byetta, Bydureon (exenatide); Trulicity (dulaglutide); Victoza, Saxenda, Xultophy (liraglutide); Ozempic, Rybelsus, Wegovy (semaglutide) and Mounjaro, Zepbound (tirzepatide). All these drugs are indicated for diabetes, while Wegovy, Saxenda, and Zepbound are also approved in the US for weight loss. (Source: Drugs.com).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.